Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in a Natalizumab Treated Population With Active Control Assessment
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Natalizumab (Primary) ; Glatiramer acetate; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 27 Jun 2012 New trial record